Thermo Fisher Scientific, a manufacturer of scientific instruments, consumables, and chemicals, completed the acquisition of Mesa Biotech, a biotechnology company, for $450m. "Mesa Biotech is an important part of our strategy to expand the benefits of molecular diagnostics at the point of care, starting with Covid-19 testing. By combining Thermo Fisher's operational excellence, access to raw materials and existing distribution and sales channels with Mesa's innovative platform, we can rapidly scale manufacturing volume, drive cost efficiencies and bring much-needed diagnostics to market faster and at greater scale," Mark Stevenson, Thermo Fisher Scientific Executive Vice President and COO.